YPSOMED HLDG SF 1415/ CH0019396990 /
| - - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| -EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 5.53 bill.EUR | - | - |
Fundamentals
| FY 2024 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 5.74 CHF | 50.26% |
| EPS Diluted: | - CHF | 50.26% |
| Revenues per Share: | 40.18 CHF | 10.25% |
| Book Value per Share: | 45.26 CHF | 9.85% |
| Cash Flow per Share: | 11.96 CHF | 26.01% |
| Dividend per Share: | 2.00 CHF | 53.85% |
| Total | in mill. | |
| Revenues: | 548.46 CHF | 10.25% |
| Net Income: | 78.37 CHF | 52.83% |
| Operating Cash Flow: | 163.22 CHF | - |
| Cash and Cash Equivalents: | 74.02 CHF | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 66.20 | 62.80 |
| P/S Ratio: | 9.46 | 8.97 |
| P/BV ratio: | 8.40 | 7.97 |
| P/CF Ratio: | 31.78 | 30.15 |
| PEG: | 1.32 | 1.25 |
| Earnings Yield: | 1.51% | 1.59% |
| Dividend Yield: | 0.53% | 0.55% |
| Market Capitalization | ||
| Market Capitalization: | 5.53 bill. EUR | 5.25 bill. EUR |
| Free Float Market Cap.: | - EUR | - EUR |
| Market Cap. / Employee: | 2.32 mill. EUR | 2.2 mill. EUR |
| Shares Outstanding: | 13.65 mill. | |
Profitability
| Gross Profit Margin: | 34.47% |
| EBIT Margin: | 15.72% |
| Net Profit Margin: | 14.29% |
| Return on Equity: | 12.69% |
| Return on Assets: | 7.12% |
Financial Strength
| Liquidity I / Cash Ratio: | 16.81% |
| Liquidity II / Quick Ratio: | 45.90% |
| Liquidity III / Current Ratio: | 76.77% |
| Debt / Equity Ratio: | 78.30% |
| Dynam. Debt / Equity Ratio: | 296.32% |
Efficiency
| Employees: | 2,389 |
| Personal Expenses / Employee: | - CHF |
| Revenues / Employee: | 229,575.97 CHF |
| Net Income / Employee: | 32,802.85 CHF |
| Total Assets / Employee: | 461,027.63 CHF |
| * Fiscal Year End: | 3/31/2024 |
| Accounting Standard: | Swiss GAAP FER |
| Currency: | CHF |
